Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Clinical trial NCT01465334 · TERMINATED
Trial details
- NCT number
- NCT01465334
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-12-01
- Primary completion
- 2014-11-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.